Estadísticas

 array:17 [
  "pii" => "X1699258X18624052"
  "issn" => "1699258X"
  "estado" => "S300"
  "fechaPublicacion" => "2018-01-01"
  "documento" => "article"
  "subdocumento" => "fla"
  "cita" => "Reumatol Clin. 2018;14 Supl 1:35-41"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1460
    "formatos" => array:3 [
      "EPUB" => 145
      "HTML" => 475
      "PDF" => 840
    ]
  ]
  "itemAnterior" => array:14 [
    "pii" => "X1699258X18624036"
    "issn" => "1699258X"
    "estado" => "S300"
    "fechaPublicacion" => "2018-01-01"
    "documento" => "article"
    "subdocumento" => "fla"
    "cita" => "Reumatol Clin. 2018;14 Supl 1:28-34"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3266
      "formatos" => array:3 [
        "EPUB" => 156
        "HTML" => 1172
        "PDF" => 1938
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Rol de la interleucina-17 en otras enfermedades y comorbilidades"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "28"
          "paginaFinal" => "34"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Role of interleukin-17 in other diseases and comorbidities"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Rubén Queiro-Silva"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Rubén"
              "apellidos" => "Queiro-Silva"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1699258X18624036?idApp=UINPBA00004M"
    "url" => "/1699258X/00000014000000S1/v0_201803261703/X1699258X18624036/v0_201803261703/es/main.assets"
  ]
  "es" => array:11 [
    "idiomaDefecto" => true
    "titulo" => "Implicaciones terapéuticas de la interleucina-17 en otras enfermedades y comorbilidades"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "35"
        "paginaFinal" => "41"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Julio Ramírez García"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Julio"
            "apellidos" => "Ramírez García"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Unidad de Artritis&#44; Servicio de Reumatolog&#237;a&#44; Hospital Cl&#237;nic i Provincial&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Therapeutic implications of interleukin-17 in other diseases and comorbidities"
      ]
    ]
    "pdfFichero" => "273v14nExtr.1a90462405pdf001.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec968540"
          "palabras" => array:5 [
            0 => "Inhibidores de IL&#45;17"
            1 => "Psoriasis"
            2 => "Artritis reumatoide"
            3 => "Enfermedad inflamatoria intestinal"
            4 => "Uve&#237;tis"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec968541"
          "palabras" => array:5 [
            0 => "Interleukin&#45;17 inhibitors"
            1 => "Psoriasis"
            2 => "Rheumatoid arthritis"
            3 => "Inflammatory bowel disease"
            4 => "Uveitis"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "Al igual que en artritis psori&#225;sica y espondilitis anquilosante&#44; los inhibidores de la IL&#45;17 han seguido un desarrollo cl&#237;nico en otras enfermedades inmunomediadas como la psoriasis&#44; la artritis reumatoide&#44; la enfermedad inflamatoria intestinal o la uve&#237;tis&#44; con resultados desiguales&#46; Mientras que en psoriasis el beneficio cl&#237;nico es muy destacado&#44; en artritis reumatoide y uve&#237;tis a&#250;n est&#225; por determinar su utilidad&#46; En enfermedad inflamatoria intestinal&#44; los datos disponibles hasta la fecha parecen descartar el beneficio del bloqueo de IL&#45;17 en esta patolog&#237;a&#46;"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "As in psoriatic arthritis and ankylosing spondylitis&#44; interleukin &#40;IL&#41;-17 inhibitors have undergone clinical development in other immune-mediated diseases such as psoriasis&#44; rheumatoid arthritis&#44; inflammatory bowel disease and uveitis&#44; with varying results&#46; While in psoriasis&#44; the clinical benefit is highly notable&#44; in rheumatoid arthritis and uveitis&#44; their utility has yet to be determined&#46; In inflammatory bowel disease&#44; the data available to date seem to rule out a benefit of IL&#45;17 blockade in this disorder&#46;"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/1699258X/00000014000000S1/v0_201803261703/X1699258X18624052/v0_201803261703/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "73100"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Interleucina-17 A&#58; Fundamentos b&#225;sicos y efectos terap&#233;uticos de su inhibici&#243;n en la espondilitis anquilosante y la artritis psori&#225;sica"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/1699258X/00000014000000S1/v0_201803261703/X1699258X18624052/v0_201803261703/es/273v14nExtr.1a90462405pdf001.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1699258X18624052?idApp=UINPBA00004M"
]